Analysts assume third quarter earnings for the companies in the S&P 500 will be bad. But, looking at the number which is the average of all firms in the index is misleading.…
Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading up on a very weak trading day after what many had deemed…
ImClone Systems Inc. (NASDAQ: IMCL) is among the biotech bonanza merger candidates with one deal on the table and perhaps an unofficial deal waiting in the wings. Bristol-Myers Squibb Co. (NYSE: BMY)…
Douglas A. McIntyre According to Reuters, Wilbur Ross say the bailout package does not address the core of problem which is mortgage payments. Reuters writes that the National Retail Federation says that this will be…
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II…
Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was…
Douglas A. McIntyre ImClone Systems Inc. (NASDAQ: IMCL) is a biotech buyout bonanza stock that traders and investors have been watching closely. The company has said that the proposed $60.00 per share cash buyout from…
Douglas A. McIntyre According to Reuters, large Yahoo! (YHOO) holder Capital Research want to know whether vote counts from the company’s annula meeting were accurate. Reuters writes that the Fed is seen as holding rates…
Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regarding the cash buyout of the company. The company’s board of directors…
Douglas A. McIntyre According to Reuters, GM (GM) is expected to post a huge loss. Reuters reports that oil company profits rose, but Exxon (XOM) missed its numbers. Reuters reported that stressed banks borrowed a…
Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share. As per…
Douglas A. McIntyre ImClone Systems Incorporated (NASDAQ: IMCL) has just announced that ERBITUX(R) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC). This approval will allow…
Douglas A. McIntyre If you thought this was a bad day for the market with the DJIA trading well under that 12,000 psychological level, there were some 400 stocks that hit 52-week lows today when…
These are ten of the analyst calls we are focusing on this Wednesday morning in pre-market trading: Bristol-Myers (NYSE: BMY) cut to Neutral at Cowen. Marriott (NYSE: MAR) cut to Perform at…
Bristol-Myers Squibb (NYSE: BMY) has submitted an open shelf offering today for an undetermined amount. The offering includes a combination of debt securities, preferred stock, depositary shares, common stock, and warrants to…
Douglas A. McIntyre 